



SAFETY DATA SHEET

Revision date 16-Jun-2025

Version 5

Page 1 / 10

Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1. Product identifier

Product Name	Deferoxamine Mesylate for Injection, USP (Hospira, Inc.)
Product Code(s)	PZ03412
Synonyms	Desferrioxamine Mesilate; Desferrioxamine Mesylate
Trade Name:	Deferoxamine Mesylate for Injection, USP
Chemical Family:	Not determined

1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use	Pharmaceutical active for the treatment of iron intoxication/overload
------------------------	---

1.3. Details of the supplier of the safety data sheet

Hospira, A Pfizer Company
275 North Field Drive
Lake Forest, Illinois 60045
1-800-879-3477

Pfizer Ireland Pharmaceuticals
OSG Building
Ringaskiddy, Co. Cork.
Ireland
+353 21 4378701

E-mail address	pfizer-MSDS@pfizer.com
-----------------------	------------------------

1.4. Emergency telephone number

Emergency Telephone	Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887
----------------------------	---

Section 2: HAZARDS IDENTIFICATION

2.1. Classification of the substance or mixture

GHS - Classification: This substance is classified as not hazardous according to regulation (EC) 1272/2008 [CLP].

OSHA Classification

Hazards not otherwise classified (HNOC)

Not applicable

Hazards classified under paragraph (d)(1)(ii) of 1910.1200

Not applicable

2.2. Label elements

Signal word	Not classified
Hazard statements	Not classified in accordance with international standards for workplace safety.

2.3. Other hazards

Other hazards	An Occupational Exposure Value has been established for this substance (see Section 8).
----------------------	---

SAFETY DATA SHEET

Product Name Deferoxamine Mesylate for Injection, USP (Hospira, Inc.)
Revision date 16-Jun-2025

Page 2 / 10
Version 5

PBT & vPvB

The product does not contain any substance(s) classified as PBT or vPvB.

Endocrine Disruptor Information

This product does not contain any known or suspected endocrine disruptors.

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Hazardous

Chemical name	Weight-%	REACH registration number	EC No (EU Index No)	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Deferoxamine Mesylate (CAS #: 138-14-7)	100		205-314-3	Not classified	Not classified	No data available	No data available

Full text of H- and EUH-phrases: see section 16

Acute Toxicity Estimate No information available

Chemical name	Oral LD50 mg/kg	Dermal LD50 mg/kg	Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
Deferoxamine Mesylate 138-14-7	17300	No data available	No data available	No data available	No data available

This product does not contain candidate substances of very high concern at a concentration $\geq 0.1\%$ (Regulation (EC) No. 1907/2006 (REACH), Article 59).

Additional information

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

Section 4: FIRST AID MEASURES

4.1. Description of first aid measures

Inhalation

Remove to fresh air. Seek immediate medical attention/advice.

Eye contact

If symptoms persist, call a physician.

Skin contact

Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

SAFETY DATA SHEET

Product Name Deferoxamine Mesylate for Injection, USP (Hospira, Inc.)
Revision date 16-Jun-2025

Page 3 / 10
Version 5

Ingestion

Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

4.2. Most important symptoms and effects, both acute and delayed

Most important symptoms and effects

For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

4.3. Indication of any immediate medical attention and special treatment needed

Note to physicians

None.

Section 5: FIRE-FIGHTING MEASURES

5.1. Extinguishing media

Suitable Extinguishing Media

Dry chemical, CO2, alcohol-resistant foam or water spray.

5.2. Special hazards arising from the substance or mixture

Specific hazards arising from the chemical

Fine particles (such as dust and mists) may fuel fires/explosions.

Hazardous combustion products

Emits toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, sulfur oxides and other sulfur-containing compounds.

Explosion data

Sensitivity to mechanical impact No information available.

Sensitivity to static discharge No information available.

5.3. Advice for firefighters

Special protective equipment and precautions for fire-fighters

Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.

Section 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

For emergency responders

Use personal protection recommended in Section 8.

6.2. Environmental precautions

Environmental precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

6.3. Methods and material for containment and cleaning up

Methods for containment Methods for cleaning up

Prevent further leakage or spillage if safe to do so.
Contain the source of the spill or leak. Collect spilled material by a method that controls dust generation. Avoid use of a filtered vacuum to clean spills of dry solids. Clean contaminated surface thoroughly.

Prevention of secondary hazards

Clean contaminated objects and areas thoroughly observing environmental regulations.

6.4. Reference to other sections

SAFETY DATA SHEET

Product Name Deferoxamine Mesylate for Injection, USP (Hospira, Inc.)
Revision date 16-Jun-2025

Page 4 / 10
Version 5

Reference to other sections See section 8 for more information. See section 13 for more information.

Section 7: HANDLING AND STORAGE

7.1. Precautions for safe handling

Advice on safe handling

Minimize dust generation and accumulation. Avoid breathing dust/fume/gas/mist/vapors/spray. Avoid contact with skin, eyes or clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

General hygiene considerations

Handle in accordance with good industrial hygiene and safety practice.

7.2. Conditions for safe storage, including any incompatibilities

Storage Conditions

Store as directed by product packaging.

7.3. Specific end use(s)

Specific use(s)

Pharmaceutical drug product.

Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control parameters

Pfizer Occupational Exposure Band (OEB) Statement:

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

8.2. Exposure controls

Engineering controls

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal protective equipment

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

Eye/face protection

Wear safety goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).

SAFETY DATA SHEET

Product Name Deferoxamine Mesylate for Injection, USP (Hospira, Inc.)
Revision date 16-Jun-2025

Page 5 / 10
Version 5

Hand protection	Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).
Skin and body protection	Wear impervious protective clothing to prevent skin contact. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).
Respiratory protection	Under normal conditions of use, if the applicable Occupational Exposure Band (OEB) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEB (e.g. particulate respirator with a full mask, P3 filter). (Respirators must meet the standards in accordance with EN136, EN143, ASTM F2704-10 or international equivalent.).
Thermal hazards	No information available.
Environmental exposure controls	No information available.

Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

Physical state	Powder
Color	White to off-white
Odor	No information available.
Odor threshold	No information available
Property	Values
Melting point / freezing point	148-149
Boiling point or initial boiling point and boiling range	No data available
Flammability (solid, gas)	No data available
Lower and upper explosion limit/flammability limit	
Lower explosion limit	No data available
Upper explosion limit	No data available
Flash point	No data available
Autoignition temperature	No data available
Decomposition temperature	
SADT (°C)	No data available
pH	3.7-5.5
pH (as aqueous solution)	No data available
Kinematic viscosity	No data available
Dynamic viscosity	No data available
Solubility	slightly soluble methanol Soluble Water
Vapor pressure	No data available
Density and/or relative density	No data available
Bulk density	No data available
Liquid Density	No data available
Vapor density	No data available
Particle characteristics	
Particle Size	No information available
Particle Size Distribution	No information available

9.2. Other information

Molecular formula	C25H48N6O8 . CH4O3S
Molecular weight	656.79

9.2.1. Information with regard to physical hazard classes

SAFETY DATA SHEET

Product Name Deferoxamine Mesylate for Injection, USP (Hospira, Inc.)
Revision date 16-Jun-2025

Page 6 / 10
Version 5

No information available

Oxidizing properties

None

9.2.2. Other safety characteristics

No information available

Section 10: STABILITY AND REACTIVITY

10.1. Reactivity

Reactivity No information available.

10.2. Chemical stability

Stability Stable under normal conditions.

Explosion data

Sensitivity to mechanical impact No information available.

Sensitivity to static discharge No information available.

10.3. Possibility of hazardous reactions

Possibility of hazardous reactions No information available.

10.4. Conditions to avoid

Conditions to avoid Fine particles (such as dust and mists) may fuel fires/explosions.

10.5. Incompatible materials

Incompatible materials As a precautionary measure, keep away from strong oxidizers.

10.6. Hazardous decomposition products

Hazardous decomposition products No data available.

Section 11: TOXICOLOGICAL INFORMATION

11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

Short term

Not acutely toxic (based on animal data)

Long Term:

Animal studies have shown a potential to cause adverse effects on the fetus.

Known Clinical Effects:

Adverse effects seen in clinical use include gastrointestinal discomfort, dizziness, and headache. Effects on vision and hearing have been seen during clinical use.

Acute toxicity

Based on available data, the classification criteria are not met.

Serious eye damage/eye irritation

Based on available data, the classification criteria are not met.

Skin corrosion/irritation

Based on available data, the classification criteria are not met.

Respiratory or skin sensitization

Based on available data, the classification criteria are not met.

STOT - single exposure

Based on available data, the classification criteria are not met.

STOT - repeated exposure

Based on available data, the classification criteria are not met.

Reproductive toxicity

Based on available data, the classification criteria are not met.

Germ cell mutagenicity

Based on available data, the classification criteria are not met.

Carcinogenicity

Based on available data, the classification criteria are not met.

Aspiration hazard

Based on available data, the classification criteria are not met.

Acute Toxicity: (Species, Route, End Point, Dose)

Deferoxamine Mesylate

Rat Oral LD50 17300 mg/kg

Rat Para-periosteal LD50 330 mg/kg

Rat Subcutaneous LD50 5500 mg/kg

Mouse Oral LD50 15200 mg/kg

Mouse Intravenous LD50 273 mg/kg

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Deferoxamine Mesylate	= 17300 mg/kg (Rat)	-	-

SAFETY DATA SHEET

Product Name Deferoxamine Mesylate for Injection, USP (Hospira, Inc.)
Revision date 16-Jun-2025

Page 7 / 10
Version 5

--	--	--	--

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Deferoxamine Mesylate

Embryo / Fetal Development Rabbit Oral 180 mg/kg/day LOAEL Developmental toxicity
Embryo / Fetal Development Mouse Oral 180 mg/kg/day LOAEL Developmental toxicity
Embryo / Fetal Development Rat Oral 180 mg/kg/day NOAEL No effects at maximum dose
Embryo / Fetal Development Mouse Intraperitoneal 352 mg/kg/day LOAEL Maternal Toxicity, Fetotoxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Deferoxamine Mesylate

In Vitro Direct DNA Interaction Human Lymphocytes Positive

Carcinogenicity Not listed as a carcinogen by IARC, NTP or US OSHA.

11.2. Information on other hazards

11.2.1. Endocrine disrupting properties

Endocrine disrupting properties Based on available data, the classification criteria are not met.

11.2.2. Other information

Other adverse effects No information available.

Section 12: ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

12.1. Toxicity

12.2. Persistence and degradability

Persistence and degradability No information available.

12.3. Bioaccumulative potential

Bioaccumulation No information available.

12.4. Mobility in soil

Mobility in soil No information available.

12.5. Results of PBT and vPvB assessment

PBT and vPvB assessment Based on available data, the classification criteria are not met.

SAFETY DATA SHEET

Product Name Deferoxamine Mesylate for Injection, USP (Hospira, Inc.)
Revision date 16-Jun-2025

Page 8 / 10
Version 5

12.6. Endocrine disrupting properties

Endocrine disrupting properties Based on available data, the classification criteria are not met.

12.7. Other adverse effects

Other adverse effects No information available.

PMT or vPvM properties Based on available data, the classification criteria are not met.

Section 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods

Waste from residues/unused products

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

UN number:	Not applicable
UN proper shipping name:	Not applicable
Transport hazard class(es):	Not applicable
Packing group:	Not applicable
Environmental Hazard(s):	Not applicable

Section 15: REGULATORY INFORMATION

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Deferoxamine Mesylate	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
EINECS	205-314-3

National regulations

Germany

Chemical Prohibition Ordinance (ChemVerbotsV)
Not applicable

SAFETY DATA SHEET

Product Name Deferoxamine Mesylate for Injection, USP (Hospira, Inc.)
Revision date 16-Jun-2025

Page 9 / 10
Version 5

TRGS 905

Not applicable

Switzerland

Ordinance on the Incentive Tax on Volatile Organic Compounds (OVOC) SR 814.018 Not applicable
Storage of Hazardous Material Not applicable
WPO (GSchV) SR 814.201; WPA (GSchG) SR 814.20 Not applicable
Major Accidents Ordinance SR 814.012 Not applicable

European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work.

Authorizations and/or restrictions on use:

This product does not contain substances subject to authorization (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Persistent Organic Pollutants

Not applicable

Ozone-depleting substances (ODS) Regulation (EU) 2024/590

Not applicable.

Explosives Precursors Marketing and Use (2019/1148)

Not applicable

Legend:

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory
DSL/NDL - Canadian Domestic Substances List/Non-Domestic Substances List
EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances
ENCS - Japan Existing and New Chemical Substances
IECSC - China Inventory of Existing Chemical Substances
KECL - Korean Existing Chemicals Inventory
PICCS - Philippines Inventory of Chemicals and Chemical Substances
AICS - Australian Inventory of Chemical Substances
NZIoC - New Zealand Inventory of Chemicals
TCSI - Taiwan Chemical Substance Inventory

15.2. Chemical safety assessment

Chemical Safety Report No information available

Section 16: OTHER INFORMATION

Key or legend to abbreviations and acronyms used in the safety data sheet

Data Sources:

The data contained in this SDS may have been gathered from confidential internal sources, raw material suppliers, or from the published literature.

SAFETY DATA SHEET

Product Name Deferoxamine Mesylate for Injection, USP (Hospira, Inc.)
Revision date 16-Jun-2025

Page 10 / 10
Version 5

Reason for revision Updated Section 2 - Hazard Identification. Updated Section 11 - Toxicology Information.
Updated Section 12 - Ecological Information.

Revision date 16-Jun-2025

Prepared By Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.